Spero Therapeutics (NASDAQ:SPRO) Stock Rating Upgraded by TD Cowen

Spero Therapeutics (NASDAQ:SPRO) was upgraded by equities researchers at TD Cowen from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Benzinga reports.

Other equities analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday.

Spero Therapeutics Price Performance

SPRO remained flat at $1.34 during trading on Tuesday. 166,391 shares of the company traded hands, compared to its average volume of 221,704. The stock has a market capitalization of $72.35 million, a P/E ratio of 3.08 and a beta of 0.63. Spero Therapeutics has a 1-year low of $0.99 and a 1-year high of $1.89. The stock has a 50 day moving average of $1.38 and a 200-day moving average of $1.51.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.17). The firm had revenue of $9.27 million for the quarter, compared to analyst estimates of $16.80 million. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. Equities research analysts predict that Spero Therapeutics will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Spero Therapeutics

Several hedge funds have recently bought and sold shares of SPRO. Virtu Financial LLC bought a new stake in Spero Therapeutics in the first quarter valued at approximately $31,000. Acadian Asset Management LLC increased its holdings in shares of Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after acquiring an additional 418,742 shares during the last quarter. Murchinson Ltd. raised its stake in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after acquiring an additional 11,210 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Spero Therapeutics during the 4th quarter valued at $1,570,000. Finally, Vanguard Group Inc. boosted its position in Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the period. 25.60% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.